Daxor Corporation (NASDAQ:DXR) Sees Large Increase in Short Interest

Daxor Corporation (NASDAQ:DXR) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 8,248 shares, an increase of 159.8% from the December 15th total of 3,175 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 4,196 shares, the days-to-cover ratio is currently 2.0 days. Based on an average daily trading volume, of 4,196 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.4% of the company’s stock are sold short.

Institutional Trading of Daxor

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. bought a new position in Daxor Corporation (NASDAQ:DXR) in the second quarter, according to its most recent filing with the SEC. The firm bought 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor as of its most recent SEC filing. 1.34% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Daxor Stock Down 2.5%

Shares of NASDAQ:DXR opened at $13.88 on Wednesday. The business’s 50-day moving average is $13.23 and its 200 day moving average is $11.98. Daxor has a 1 year low of $6.55 and a 1 year high of $14.76.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.